secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001628280-24-002715
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo regains Nasdaq minimum bid compliance; subject to 1-year panel monitor
----------------------------------------------------------------------------

- Received Nasdaq letter January 30, 2024 confirming compliance with $1.00 bid price rule.
- Reverse stock split on December 28, 2023 brought stock above $1.00 since December 29, 2023.
- Mandatory panel monitor for one year from January 30, 2024; no cure period if noncompliant again.
- If noncompliant during monitor, Nasdaq will issue delist letter; company can request hearing.
- Failure to satisfy panel could result in delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024002715/0001628280-24-002715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024002715/avtx-20240130.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-002715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer